A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 129



James Bean, Cameron Brennan, Jin-Yuan Shih, Gregory Riely, Agnes Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, Janos Szoke, Stephen Broderick, Marissa Balak, Wen-Cheng Chang, Chong-Jen Yu, Adi Gazdar, Harvey Pass, Valerie Rusch, William Gerald, Shiu-Feng Huang, Pan-Chyr Yang, Vincent Miller, Marc Ladanyi, Chih-Hsin Yang, William Pao. Proc Natl Acad Sci U S A 2007
Times Cited: 1277




List of shared articles



Times cited

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, Jian-Hua Chang, Gong-Yan Chen, Jian Xing He, Wei Li, Xiao-Qing Liu, Nong Yang, Caicun Zhou,[...]. Invest New Drugs 2021
1

Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I Shapiro, Mark A Socinski, Danielle A Murphy, Umberto Conte,[...]. J Thorac Oncol 2021
6

Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
Keunchil Park, Gee-Chen Chang, Giuseppe Curigliano, Wan-Teck Lim, Ross A Soo, Miguel A Molina-Vila, Valérie Cattan, Hélène Darville, Eric Gandossi, Veronika Smutna,[...]. Lung Cancer 2021
2

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Matthew Lee, Prantesh Jain, Feng Wang, Patrick C Ma, Alain Borczuk, Balazs Halmos. Expert Opin Ther Targets 2021
1

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.
Caroline E McCoach, Aiming Yu, David R Gandara, Jonathan W Riess, Daniel P Vang, Tiahong Li, Primo N Lara, Matthew Gubens, Frances Lara, Philip C Mack,[...]. JCO Precis Oncol 2021
1


Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
Victor Moreno, Richard Greil, Jeffrey Yachnin, Margarita Majem, Martin Wermke, Hendrik-Tobias Arkenau, Jean-Rene Basque, Prasanna Kumar Nidamarthy, Shruti Kapoor, Xiaoming Cui,[...]. Clin Ther 2021
0

HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence.
Jianjiang Fu, Xiaorui Su, Zhihua Li, Ling Deng, Xiawei Liu, Xuancheng Feng, Juan Peng. Oncogene 2021
3

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.
Pınar Özden Eser, Raymond M Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Heidi M Haikala, Ciric To, Jeffrey J Okoro, Kshiti H Dholakia, Jihyun Choi,[...]. Sci Transl Med 2021
0

MET Amplification in Non-Small Cell Lung Cancer (NSCLC)-A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting.
Christoph Schubart, Robert Stöhr, Lars Tögel, Florian Fuchs, Horia Sirbu, Gerhard Seitz, Ruth Seggewiss-Bernhardt, Rumo Leistner, William Sterlacci, Michael Vieth,[...]. Cancers (Basel) 2021
0

Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach.
Elena M Tosca, Glenn Gauderat, Sylvain Fouliard, Mike Burbridge, Marylore Chenel, Paolo Magni. CPT Pharmacometrics Syst Pharmacol 2021
2

Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization.
Christina Schmitt, Anna-Alice Schulz, Ria Winkelmann, Kevin Smith, Peter J Wild, Melanie Demes. Oncotarget 2021
0

First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.
Xingsheng Hu, Xin Zheng, Sheng Yang, Lin Wang, Xuezhi Hao, Xinge Cui, Lieming Ding, Li Mao, Pei Hu, Yuankai Shi. J Hematol Oncol 2020
1


Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
M Schuler, R Berardi, W-T Lim, M de Jonge, T M Bauer, A Azaro, M Gottfried, J-Y Han, D H Lee, M Wollner,[...]. Ann Oncol 2020
30

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Jean-Pierre Delord, Guillem Argilés, Jerôme Fayette, Lori Wirth, Stefan Kasper, Salvatore Siena, Ricard Mesia, Rossana Berardi, Andrés Cervantes, Jeroen Dekervel,[...]. Invest New Drugs 2020
3

Progress on treatment of MET signaling pathway in non-small cell lung cancer.
Xiaoqing Yu, Sizhe Yu, Yun Fan. Int J Clin Oncol 2020
1



MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
37

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Yubo Wang, Panwen Tian, Lei Xia, Li Li, Rui Han, Mengxiao Zhu, Analyn Lizaso, Tian Qin, Min Li, Bing Yu,[...]. Lung Cancer 2020
6



Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Expert Opin Emerg Drugs 2020
5

The METeoric rise of MET in lung cancer.
Alex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, Solange Peters, Alfredo Addeo. Cancer 2020
7